risenhoover,,2019-06-03 12:47:00,37.96,AZN AstraZeneca files form 6K httpsfinteliosusazn
luigirossi223,True,2019-06-03 11:44:00,38.105,SPHS The CEO of AZN Pascal Soriot was talking about treating pancreatic cancer with mention of treating prostate cancer on CNBC just now AZN could become a leader in treating prostate cancer along with BPH in 12 to 18 months using topsalysin PRX302 The drug has had no side effects and is a proven safe track record in recent trials In addition to ablating cancer tumors Sophiris Bio Inc SPHS is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia BPH The companys lead candidate topsalysin PRX302 is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen PSA which is produced in large quantities by the prostate gland AstraZeneca PLC NYSE AZN Sophiris Bio Inc NASDAQ SPHS
risenhoover,,2019-06-03 11:36:00,38.06,AZN AstraZeneca files form 6K httpsfinteliosusazn
michael82929,True,2019-06-03 11:28:00,38.015,AMRN GSK MTNB AZN omegasectorisgoingtobeamonster
